Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GLUE
GLUE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GLUE News
Activist Investors Target Staar Surgical, Alumis, and Other Stocks
Jan 17 2026
Barron's
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Monte Rosa Therapeutics Prices $11.1 Million Public Offering
Jan 09 2026
Yahoo Finance
Monte Rosa (GLUE) Prices 11.125M Share Offering at $24, Anticipates $300M Proceeds
Jan 09 2026
NASDAQ.COM
Monte Rosa Prices 11.125M Shares at $24 Each, Raising $300M
Jan 09 2026
Globenewswire
Monte Rosa Prices Public Offering of 11.125M Shares at $24 Each, Raising $300M
Jan 09 2026
Yahoo Finance
Monte Rosa Therapeutics (GLUE) Stock Surpasses Analyst Target Price of $22.70
Jan 08 2026
NASDAQ.COM
US Stock Market Volatile, Nasdaq Hits 3.5-Week High
Jan 08 2026
NASDAQ.COM
S&P 500 Hits All-Time High Amid Mixed Economic Signals
Jan 07 2026
NASDAQ.COM
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
Jan 07 2026
Benzinga
S&P 500 Hits All-Time High as Stock Indexes Mostly Rise
Jan 07 2026
NASDAQ.COM
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Monte Rosa Reports MRT-8102 Interim Data Showing 85% hsCRP Reduction in Phase 1 Study
Jan 07 2026
Benzinga
Monte Rosa Therapeutics (GLUE) Reports 85% CRP Reduction in MRT-8102 Phase 1 Study
Jan 07 2026
NASDAQ.COM
Monte Rosa Therapeutics (GLUE) Reports 85% Reduction in Inflammation from MRT-8102 Phase 1 Study
Jan 07 2026
NASDAQ.COM
Monte Rosa Therapeutics (GLUE) Rises $6.87 to $22.88 with 5.7M Shares Traded
Jan 07 2026
NASDAQ.COM
Show More News
